AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06219590 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Shame Acetylcholine Iontophoresis
Description: Shame Acetylcholine Iontophoresis 15 min/ three sessions/ week for two weeks.
Study NCT05468788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention: Integrative Community Therapy-based Psychodrama
Description: Participants produce theatre scenes depicting issues that they have experienced. Group leaders then use a guide to facilitate a discussion of participants' feelings, coping strategies, and sharing of local knowledge.
Study NCT05468788 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control: Improvisational Theatre
Description: Participants play improvisational theatre games.
Study NCT06320912 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The intraparenchymal portal vein covered stent
Description: The intraparenchymal portal vein covered stent, produced by Shanghai Shenqi Medical Technology Co., Ltd., is used for a transjugular approach. It establishes an artificial shunt between the hepatic vein and the main branches of the portal vein within the liver. This helps in reducing portal venous pressure and alleviating or improving the symptoms of portal hypertension and its complications, such as variceal bleeding, gastropathy, refractory ascites, and/or hepatic hydrothorax.
Study NCT06320912 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TIPS Covered Stent System GORE
Description: The GORE® VIATORR® Transjugular Intrahepatic Portosystemic Shunt (TIPS) Covered Stent consists of an implantable covered stent and a percutaneous delivery catheter.
Study NCT05757882 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 4 hours of fasting time
Description: Oral intake is not allowed for 4 hours before sedation including water.
Study NCT05757882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 hours of fasting time
Description: Oral intake is not allowed for 2 hours before sedation including water.
Study NCT05663190 — intervention group
Intervention type: OTHER
Intervention: mental foramen location
Description: location of mental foramen in relation to primary molars
Study NCT06376396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albendazole and praziquantel
Description: Combination of albendazole plus praziquantel
Study NCT06376396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Albendazole alone
Study NCT05874141 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Electrocardiography (ECG)
Description: by electrocardiogram
Study NCT05874141 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transthoracic echocardiography, Neck ultrasonography if needed and abdominopelvic ultrasound
Description: imaging
Study NCT05874141 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arterial duplex ultrasound of both lower limbs
Description: imaging
Study NCT05874141 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Random blood glucose
Description: serum sample
Study NCT05874141 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: AST, ALT, albumin
Description: serum sample
Study NCT04528238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxing Visual Immersion
Description: During the intravenous treatment for cancer, a nature movie will be projected on the ceiling of the room, along with natural sounds or a relaxing music. The patient will choose the movie or movies he wants to watch and can decide to stop the Relaxing Visual Immersion (RVI) at any time. The RVI is a system that does not isolate the patient from his familiar or medical entourage and which integrates virtual scenarios in the environment of care.
Study NCT05518461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iThrive WI Intervention
Description: Participants will receive COVID-19 and overdose-related educational and motivational content over the course of 12 weeks through the Thrive4Life Connect, a mobile health application. They will be invited to set goals for lowering overdose and COVID-19 risk.
Study NCT04802603 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Spine stereotactic body radiotherapy
Description: Cohort 1 - De novo: Spine stereotactic body radiotherapy to a dose of 40 Gy in 5 fractions.~Cohort 2 - Prior radiotherapy: Risk-adapted spinal cord tolerance based on prior spine stereotactic body radiotherapy to a dose of 40 Gy in 5 fractions.
Study NCT06026280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DRIVEN Application
Description: Participants will complete the six-week DRIVEN program, which includes a smartphone application and job coaching.
Study NCT06026280 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Career Resources
Description: Participants will receive weekly information about job-searching skills and resources from a study coordinator for six weeks.
Study NCT06135948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extra dose of L-thyroxine, 25 mcg during Ramadan
Description: Extra dose of L-thyroxine, 25 mcg during the month of Ramadan
Study NCT06499714 — intervention group
Intervention type: OTHER
Intervention: Exposure to 3600 m
Description: Participants will travel to and stay for 2 days at an altitude of 3600 m.
Study NCT06445257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zanubrutinib 160 mg BID orally
Description: The ZRMT induction and maintenance regimen
Study NCT05806255 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The RELIEF App
Description: RELIEF is a virtual app designed for the remote self-reporting of symptoms in patients with palliative care needs. The patient/caregiver securely logs into the site and self-reports symptoms, distress, and pain using the validated clinical tools ESAS-r, Distress Thermometer (DT), and Brief Pain Inventory (BPI) currently in daily use by healthcare providers across Canada.~This data is reported to the healthcare providers via RELIEF. Any increases in symptom burden, distress, or pain are flagged for clinical review as RELIEF alerts. Healthcare providers received alerts via secure email for any sudden changes in symptom status, or if the patient's symptoms, distress, or pain severity increases by set amounts over a period of time. Following review of the RELIEF alert by the healthcare providers, patients receive (1) earlier intervention; (2) mobilization of auxiliary services; and (3) recommendation for urgent clinic/home visit or emergency department visit.
Study NCT06515951 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: STANDING algorithm
Description: The STANDING algorithm is composed by four steps. The first phase consists in evaluating the presence of spontaneous nystagmus at rest for at least five minutes with and without Frenzel goggles in order to assess if a acute vestibular syndrome is present. If there is not a spontaneous nystagmus, then positional maneuvers (Pagnini-Mc Cure and Dix-Hallpike) have to be performed. Otherwise if spontaneous nystagmus is observed, its feature are fundamental to diagnose a central vertigo. If nystagmus characteristics suggest a peripheral form, the head impulse test is performed by instructing the patient to keep eyes on a fixed target and then turned the head quickly. An abnormal response is typical of vestibular neuritis. In any cases after the described maneuvers, the patient must be evaluated when standing up and walking: if this turn out to be impossibile, the test is indicative of central nervous system disease.
Study NCT05674136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00061
Description: Noninvasive pulse oximeter sensor
Study NCT05150678 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: removal of ceserean section scar
Description: we will remove the previous scar in group A
Study NCT05150678 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non removal of cesearean section scar
Description: we will open in the previous cesearean scar in group B
Study NCT04815798 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bacteriophage-loaded Microcapsule Spray
Description: Study intervention consists of a dosage-metered airless spray containing a cocktail of 14 bacteriophages encapsulated in a biodegradable polymer. This bacteriophage product will be delivered topically every 3 days for 56 days or until wound has healed.
Study NCT04815798 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intervention consists of a dosage-metered airless spray containing a buffer solution analogous to the study intervention. This placebo will be delivered topically every 3 days for 56 days or until wound has healed.
Study NCT04815798 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care consists of but is not limited to offloading, positioning, cleansing, debridement, and wound dressing. A topical antimicrobial hydrogel will applied to wounds with signs of localized infection.
Study NCT04815798 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Standard of care consists of but is not limited to offloading, positioning, cleansing, debridement, and wound dressing. A topical antimicrobial hydrogel will applied to wounds with signs of localized infection.
Study NCT06350448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Washed Microbiota Transplantation
Description: Washed microbiota suspension (5U) delivered through nasogastric tube, nasojejunal tube or oral. Dose and frequency: 5U, three times.
Study NCT04753489 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rivaroxaban film-coated tablet 10 mg
Description: Rivaroxaban is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 10 mg of rivaroxaban.
Study NCT04753489 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Xarelto® film-coated tablet 10 mg
Description: Xarelto® is manufactured by Bayer AG, Germany. Each tablet contains 10 mg of rivaroxaban.
Study NCT05399550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan
Description: Intravenous Solution
Study NCT05399550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Intravenous Solution
Study NCT05380349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combinations of up to 3 FDA approved drugs from a panel of compounds
Description: personalized drug combinations
Study NCT05021952 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mHealth App and wearable device
Description: An intervention group (App+IoT device) uses a smart care application for 12 months. This application was tailored for prostate cancer patients and created by reflecting the treatment process after surgery. And they also uses a wearable smart band for 12 months.
Study NCT06353503 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow aspirate concentrate
Description: local knee joint injection of autologous bone marrow
Study NCT05305924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant Run-In
Description: The study is evaluating if a drug holiday (post CDK inhibitors progression) will reset the cell cycle machinery to be responsive to Abemaciclib and Fulvestrant.
Study NCT05053126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 300mg
Description: Participant will receive an oral dose of pregabalin 300 mg
Study NCT05053126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin 450 mg
Description: Participant will receive an oral dose of pregabalin 450 mg
Study NCT05053126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg with oxycodone 20 mg
Description: Participant will receive an oral dose of pregabalin 300 mg and oxycodone 20 mg
Study NCT05053126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin 450 mg with oxycodone 20 mg
Description: Participant will receive an oral dose of pregabalin 450 mg and oxycodone 20 mg
Study NCT05053126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone 20 mg
Description: Participant will receive an oral dose of oxycodone 20 mg
Study NCT05053126 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participant will receive an oral dose of placebo
Study NCT06374862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobilization
Description: specific mobilization on neuromuscular functioning, thanks to surface EMG, before and after a specific mobilization of the spine
Study NCT06374862 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: no effect
Description: a mobilization identified as no effect could modulate neuromuscular activity by a placebo effect.
Study NCT06334172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin
Study NCT05350475 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton therapy
Description: Patients in the experimental arm will receive proton therapy within the same dose and fraction schedule as patients receiving photon therapy, which is standard treatment.
Study NCT05350475 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photon therapy
Description: Patients in the photon arm will receive standard treatment with photon therapy.
Study NCT06311617 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fundus photography and optical coherence tomography
Description: Non-mydriatic fundus photography and optical coherence tomography will be performed at 3 timepoints
Study NCT05231824 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavioral Weight Loss Treatment
Description: Behavioral weight loss treatment is the current gold standard treatment for obesity.
Study NCT05231824 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI-optimized Behavioral Weight Loss Treatment
Description: AI-optimized Behavioral Weight Loss Treatment will continuously vary intensity (automated text message, videoconference group, individual coaching call) and coach type (paraprofessional or MS-level expert) based on continuously-monitored participant digital data.
Study NCT05180513 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Teleconference Mindfulness Intervention
Description: The teleconference intervention is administered by a trained interventionist via Zoom and is based on a manual adapted from a traditional MBSR version. Practices and activities include meditations, mindful breathing exercises and movements, discussions, and reflections, which participants learn at weekly sessions and practice on their own throughout the week. To adapt the traditional MBSR program for the target community population, intervention materials were reviewed for feedback from community stakeholders, and modified according to their feedback.
Study NCT05180513 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smartphone App Mindfulness Intervention
Description: The smartphone app intervention is administered through the app. The smartphone app aligns with the traditional MBSR format, but training and practice is done individually and independently by members of this group. To adapt the traditional MBSR program for the target community population, the app was tested by community stakeholders and modified according to their feedback.
Study NCT05987982 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral exercises and oral hygiene
Description: The patients will be required to perform oral exercises and maintain oral hygiene twice a day. The investigators will assess their oral frailty, oral bacteria, oral odor, and other related clinical care data on the following time points: day 1 of hospitalization, day 3 of hospitalization, the day of discharge, one week after discharge, and one month after discharge.
Study NCT05987982 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral care
Description: The patients will be required to maintain oral hygiene twice a day. The investigators will assess their oral frailty, oral bacteria, oral odor, and other related clinical care data on the following time points: day 1 of hospitalization, day 3 of hospitalization, the day of discharge, one week after discharge, and one month after discharge.
Study NCT06315192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stroke Alarm
Description: Patients who meet the criteria for participation will, after signing consent, be included and receive the Stroke Alarm bracelets that are used for 3 months. Study data will be collected as baseline at inclusion, at follow-up 3 months after inclusion and by using national Swedish registry data after completion of the study.
Study NCT06334172 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT04717076 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: App-based nutritional concept and fitness tracking
Description: The App-based nutritional concept based on menu plan, which are personalized according to participants age, gender, physical activity. The App is coupled with a Smartwatch to encourage and track physical activity over the study period.
Study NCT04717076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional concept with individual nutritional counselling
Description: Nutritional concept based on personalized menu plans and individual nutritional counselling every four weeks (4 times during the study)
Study NCT04717076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional concept without individual nutritional counselling
Description: Nutritional concept based on personalized menu plans
Study NCT05187702 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional exersize
Description: Participants will be given balance and strengthening exercises covering the balance exercise protocol.
Study NCT05187702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional exersize
Description: Participants will be given balance and strengthening exercises covering the balance exercise protocol.
Study NCT05187702 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exersize
Description: 60% of the maximum heart rate is given 3 walking eccentricity per week
Study NCT00753818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DHA and ARA
Description: various levels of DHA and ARA
Study NCT05260749 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: real-time fMRI neurofeedback training procedure
Description: real-time fMRI neurofeedback training procedure running on the Turbo Brain voyager (TBV) 3.2 software (Brain Innovation, Maastricht, The Netherlands)
Study NCT05146440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM14
Description: Pharmaceutical form: PM14 drug product is provided as a sterile lyophilized powder for concentrate for solution for infusion with a strength of 5.0 mg of the active moiety.~Route of administration: PM14 drug product was developed for administration by the i.v. route. Before use, the vials are reconstituted with 10 mL of sodium chloride 9 mg/mL (0.9%) solution for infusion to give a solution containing 0.5 mg/mL of PM14. Prior to administration, the reconstituted DP solution should be further diluted with sodium chloride 9 mg/mL (0.9%) solution for infusion. Each vial of PM14 5.0 mg is a single use vial.
Study NCT04441008 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerated Intermittent Theta Burst (aiTBS)
Description: High-dose intermittent theta burst administered at a treatment frequency 10x per day, with each treatment session duration 3x standard TMS (1800 pulses). Delivering 50 sessions in 5 days.
Study NCT04441008 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive therapy (ECT)
Description: ECT as per standard clinical care and management.
Study NCT04441008 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Description: ECT as per standard clinical care and management.
Study NCT00753818 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Study NCT06425770 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: indirect digital impression and 3D printed cast
Description: the provisional restoration will be scanned with intraoral scanner extraorally, based on which a virtual model will be created, from which a 3D printed cast will be created with manually fabricated gingival mask based on the provisional restoration
Study NCT06425770 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: direct digital impression
Description: the emergence profile will be directly scanned with intraoral scanner at 0, 2, 10, and 20 minutes after removing the provisional restoration
Study NCT06425770 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional impresion and cast
Description: conventional impression with elastomer (silicon), from which a high-precision epoxi-resin cast with gingival mask will be created
Study NCT05620602 — intervention group
Intervention type: OTHER
Intervention: Remedial treatment within 3 months
Description: The interval between the time of this treatment and the last day of the last therapy is within 3 months.Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d.